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Abstract 
Background: rheumatoid arthritis (RA) is associated with the loss of overall functionality, which leads to substantial 
economic losses. Second line agents used in RA treatment require careful monitorization in terms of efficiency and tolerability. 
Objective: trends, predictive factors and characteristics of clinical, biological and radiological RA monitorization in a cross 
sectional observational cohort study, conducted on over 206 patients in Romania, with a 12 months follow up (December 2007 - 
December 2008).  
  Method: Cases were recruited from the south-west region of the country, covering a geographical area of 23 counties. 
Patients were invited to complete three sets of interviews (collected by post) in a consent letter, containing self reported 
questionnaires, at 6 months intervals: an original questionnaire (which included quantitative self reported of pain, disease activity and 
fatigue on visual analogue scale - VAS), Health Assessment Questionnaire - HAQ - Disability and Discomfort Scales and EUROQOL 
EQ-5D, validated in Romanian (obtaining a user agreement by authors of the original version).  
Results: analysis was carried out in SPSS 10. The cohort enrolled 206 patients, with the average age of 54.90 ± 12.67 
years, 66% urban, 86.4% women, 29.1% professionally active, 48.5% graduates of primary education. The average disease duration 
after diagnosis of RA was of 9.40 ± 8.87 years. The duration of the treatment reported at baseline was of 2.70 ± 2.64 years. Most 
patients followed a program of monthly monitoring at a general practitioner (GP) (41.7% at baseline and 37.1% to 12 months). Visits 
to the rheumatologist followed a monthly regimen (32.3% at baseline and 31.7% to 12 months) or a 2 months interval (19.4% at 
baseline and 29.6% to 12 months, p = 0.000). Biological monitoring was quarterly (39.6% and 53.2% at 12 months; p = 0.000) or at 2 
months interval (26.2% at baseline and 16.7% to 12 months, p = 0.000). X-ray monitoring lacked in over half the cases in a year of 
disease progression (63.3% at 6 months and 62.2% at 12 months), although it sums between 1 and 3 radiographs to one third of the 
cases (36.8%),  
Conclusion: generally, in our country, there is a lack of aggregation in the dispensarization algorithm of patients with RA; 
consequently, the decision is awarded to the human factor. Under these circumstances, some patients are over evaluated. 
Promoting a dispensarization guide for RA patients could induce benefits both clinically and economically. Therefore, we submit a 
proposal of recommendations as a guideline for clinical, biological and radiological monitoring, according to the phase and stage of 
RA.  
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Background 
Rheumatoid arthritis (RA) is a chronic 
inflammatory systemic disease, with a fluctuating 
evolution and an unpredictable prognosis [4]; it causes 
severe decline of functionality and quality of life, 
increased morbidity and mortality [3]. 
The RA treatment uses non-biological and 
biological DMARDs (disease modifying anti-rheumatic 
drugs) with significant roles in reducing and preventing 
joint damage and improving the quality of life [1.6]. 
Potential adverse events of these preparations require a 
rigorous monitoring. The aims seek to assess disease 
activity and therapeutic strategy adjustment, but also to 
prevent excess morbidity and hospitalizations related to 
tolerability [2]. 
Promoting an adequate monitoring program for 
RA patients is still a matter of international medical 
debate. [7].  
For a definite RA, ACR recommendations 
(American College of Rheumatology) provide that medical 
visits to the primary care network are between 3 and 6  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
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months, and to the rheumatologist between 6 and 12 
months [5].  
 As presented in the end of the article regarding 
the Romanian RA population "X-ray" PR, we return with 
aspects of the resource utilization, focusing on RA 
monitorization, during a period of 12 months follow up. 
Study Objective 
The study aims to estimate the characteristics, 
trends and predictive factors of RA clinical, biological and 
radiological monitoring, in a cross-sectional, observational 
cohort study, conducted on over 206 patients in Romania, 
during 12 months follow up (December 2007 - December 
2008).  
Methods 
The cases (n = 206) came from two sources. 
Some cases are hospitalized patients in the "Dr. Ion 
Cantacuzino" Hospital -Bucharest, Department of Internal 
Medicine and Rheumatology, during the year 2007. They 
have been drawn out chronologically, according to their 
time presentation, from the hospital electronic database. 
Inclusion criteria consisted of RA diagnosis and exclusion 
criteria and the presence of any malignancy. To cover a 
broader geographical area, other cases from the 
ambulatory care have been enrolled, by working with 
other rheumatologists in the country (randomly chosen 
from their patients lists, based on the same inclusion and 
exclusion criteria).  
RA diagnosis was established by the 
rheumatologist, for each patient apart.  
Through a consent-letter, we collected three 
series of interviews by mail, containing the patients’ self-
assessments, at 6 months intervals: T1 (at baseline), T2 
(at 6 months) and T3 (at 12 months) - between December 
2007 and December 2008. Because of those who failed 
the interviews no. 2 (T2) and no. 3 (T3), the initial size of 
the cohort was decreased, but statistically insignificant. 
These patients were reported as lost to follow up at T2 
and T3. Thus, from 206 cases recruited initially (at T1), at 
T2 a number of 193 subjects responded, and, at T3, 189.  
Each set of assessments consisted of three 
different questionnaires: an original questionnaire, the 
Health Assessment Questionnaire (HAQ) Disability and 
Discomfort Scales and EUROQOL EQ-5D, validated in 
Romanian (with the consent for use from the authors of 
the original version).  
The collected data were distributed in variable 
categories: socio-demographic, comorbidities, general 
and functional disease features, quality of life and 
economic impact.  
Data analyses 
The sample (n = 206) covered 23 counties, from 
the southern and western areas of the country, which led 
us to estimate that the group is representative for the 
entire RA population in our country.  
The data have been analyzed in the program 
SPSS 10; we used ANOVA, two independent samples T 
test – for the continuous variables, Chi-Square, Kruskall 
Wallis and Man Whitney tests– for non-continuous 
variables, bivariate correlations (Pearson, Spearman 
coefficients), and linear regression. 
The sample has been subdivided according to 
the therapy: one group was treated with non-biological 
DMARDs (monotherapy and combination = group A) and 
one group with biological DMARDs (group B).  
At T1, five patients were not on remission 
therapy, at T2, 4 patients, and, at T3, 11 cases. These 
subjects were excluded from the comparative analysis 
between groups.  
At the assessment times, the cohort groups 
consisted of at T1, group A = 129 cases, group B = 70 
cases, at T2, group A = 120 cases, group B = 69 cases, 
at T3, group A = 108 cases, group B = 70 cases.  
Results and discussions 
The cohort baseline characteristics are listed in 
Table 1. 
 
 
 
 
Characteristic  Sample 
n = 206 
Group Aa 
n = 129 
Group Bb 
n = 70 
p value 
Group A versus B 
Age at inclusion (years)  54.90 ± 12.67  56.76 ± 12,25  51,84 ± 11,82  0,007* 
Women   86,4%  88,4%  84,3%  NS 
Urban   66%  64,3%  67,1%  NS 
Married   75,7%  79,8%  71,4%  NS 
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Ethnicity (Romanian)  93,7%  93%  95,7%  NS 
Professional activity 
Working active 
Retired  
Unemployed  
 
29,1% 
69,4% 
1,5% 
 
29,5% 
69% 
1,6% 
 
30% 
70% 
- 
 
NS 
NS 
NS 
Education 
Not school education 
Primary education level 
Medium education level 
Superior education level 
 
1% 
48,5% 
36,9% 
13,6% 
 
1,6% 
49,6% 
37,2% 
11,6% 
 
- 
48,6% 
34,3% 
17,1% 
 
NS 
NS 
NS 
NS 
Monthly income 
< 500 lei 
500 -1000 lei 
1000 – 1500 lei 
> 1500 lei 
 
61% 
29,3% 
7,8% 
2% 
 
60,5% 
31% 
7% 
1,6% 
 
62,9% 
25,7% 
10% 
1,4% 
 
NS 
NS 
NS 
NS 
Disease duration starting 
diagnosis (ys) 
9,40 ± 8,87  8,24 ± 8,93  11,32 ± 8,30  0,01* 
Mean duration of current 
treatment (ys) 
2,70 ± 2,64  2,71 ± 2,86  2,71 ± 2,19  NS 
Results are given in average± DS for continuous variables and in percentages for non-continuous variables; a + b = 199 (7 cases 
have been excluded after splitting the sample into therapeutic groups); group A= non-biologic DMARDs; group B= biologic DMARDs; 
* Level of significance alpha: p<0,05; NS=non statistically significant  
 
 
Indicators of resource utilization in the field of RA cases monitorization are given in Table 2. 
 
 
 
 
Characteristic  T1 
n = 206 
T2 
n = 193 
T3 
n = 189 
p 
Medical visits: rheumatologist/ 6 months 
6 visits
3 visits
2 visits
0 visits
Other
4,58 ± 2.67 
 
32,3% 
19,4% 
15,4% 
3% 
29,9% 
3,74 ± 2,06 
 
31% 
31% 
14,4% 
5,3% 
18,3% 
3,82 ± 2,17 
 
31,7% 
29,6% 
17,2% 
4,8% 
16,7% 
0,000** 
 
 
< 0,01** 
 
 
< 0,01** 
Medical visits: rheumatologist/ 12 months 
Group Aa 
Group Bb
 
11,45 ± 5,57 
12,32 ± 5,86 
NS 
 
Medical visits: general practitioner/6 months 
 
6 visits
3 visits
4,49 ± 2,84 
 
41,7% 
7,5% 
3,89 ± 2,37 
 
39,5% 
17,3% 
4,24 ± 2,14 
 
37,1% 
24,7% 
≤ 0,01** 
 
 
< 0,01* 
Table 2 Indicators of clinical, biological and radiological monitoring                  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
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2 visits
0 visits
Other
8,5% 
15,6% 
26,7% 
9,7% 
13% 
20,5% 
13,4% 
3,8% 
21% 
 
< 0,01* 
 
Medical visits: general practitioner/12 months 
Group Aa
Group Bb
 
11,88 ± 5,85 
12,60 ± 6,34 
NS 
 
Lab sets/ 6 months 
3 sets
2 sets 
1 set
0 sets
Other
2,60 ± 1,40 
 
26,2% 
39,6% 
16,8% 
1% 
16,4% 
2,29 ± 1,23 
 
19,1% 
47,3% 
17,6% 
3,7% 
12,3% 
2,23 ± 1,16 
 
16,7% 
53,2% 
19,4% 
1,6% 
9,1% 
0,000** 
 
 
< 0,01** 
 
 
 
Lab sets/ 12 months 
Group Aa
Group Bb
 
6,69 ± 2,99 
7,50 ± 3,07 
0,08 
 
X-rays number/ 6 months 
 
>3 X-rays
1 – 3 X-rays
0 X-rays
1,45 ± 1,49 
 
9,4%% 
50,7% 
39,9% 
0,80 ± 1,24 
 
3,7% 
33% 
63,3% 
0,72 ± 1,09 
 
1,1% 
36,8% 
62,2% 
0,000** 
 
< 0,01** 
< 0,01** 
< 0,01** 
X-rays number/ 12 months 
Group Aa
Group Bb
 
3,29 ± 2,89 
2,26 ± 2,74 
< 0,01** 
Results are given in average± DS for continuous variables and in percentages for non-continuous variables; a: non-biologic 
DMARDs; b: group B= biologic DMARDs; * Level of significance alpha: p<0,05; ** level of significance alpha < 0,01; T1 = baseline; 
T2= at 6 months; T3 = at 12 months; NS=non statistically significant  
 
Concerning the rheumatologist’ case monitoring, there is a fluctuation in the frequency of medical visits, within 
12 months of follow up (Figure 1).  
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Thus, more than ⅓ of RA cases reported 
monthly, which represent the medical visits to the 
rheumatologist, were maintained at a constant level 
(32.3% - 31% - 31.7%). Medical checks with a regularity 
of 2 months were significantly increased in the interval T1 
– T3 (19.4% - 31% - 29.6%, p <0.001). A slightly upward 
trajectory notes medical exams at every 3 months (15.4% 
- 14.4% - 17.2%). 
The lack of compliance, assessed by the 
proportion of patients who did not submit to 
rheumatologists, increased slightly from T1 to T2 and T3, 
from 3% to 5.3% and 4.8% (Figure 1).  
In this context of lack of monitoring differentiation 
according to RA phase or stage, the most plausible 
hypothesis is that the rate of medical checks, involves the 
human factor. Furthermore, another approach brings to 
attention the fact that a closer follow up is responsible for 
a better efficiency in the evaluated parameters. 
In this latter instance, we present Figure 2, 
which reproduces the comparative evolution of HAQ 
score in the interval T1 - T3, between cases monitored 
monthly and other cases that received a more spaced 
rate of monitorization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lack of improvement in HAQ score for patients 
receiving a more intensive clinical surveillance in terms of 
rate, confirms the human factor intervention in the 
decision on rhythm of clinical monitoring of RA patients. 
Which is the contribution of the primary medical 
network in the monitorization of RA patients? The results 
dynamics is much wider. According to Figure 3, more 
than ⅓ of the cases reported medical visits monthly, with 
a small reduction at T3 (41.7% - 39.5% - 37.1%). Medical 
checks with regularity of 2 months intervals have tripled in 
volume between T1 and T3 (7.5% - 17.3% - 24.7%, p 
<0.05). The same issue is seen ascending for medical 
checks at every 3 months (8.5% - 9.7% - 13.4%, p <0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only at T3 is there an association between 
primary care monitoring rhythm and the self reported pain, 
disease activity and fatigue (on VAS) (r = 0.25, p = 0.000). 
However, there is a constant significant association 
between the visits to the primary care network and to the 
rheumatologist (ρs = 0.345, p = 0.000). When the 
hypothesis that patients call on the general practitioner 
(GP) appears, the assessments on a monthly basis are 
the same receiving monthly rheumatologist evaluation. 
A positive aspect is noted in patients who did not 
receive medical evaluation: their proportion has declined 
dramatically from 15.6% at T1 to 3.8% T at T3 (p <0.05)  
(Figure 3). 
The dynamics of the biological monitoring 
describes a change in parameters, which suggests some 
trends (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After 12 months of follow-up, one tends to focus 
on biological exploration within 3 months (for 53% of 
cases), while the extremes range include a significant 
percentage of cases (16% to 20% at 2 months and 6 
months).  
There is a constant direct correlation between 
the rate of biological monitoring and the medical visits to 
the primary network (ρs = 0.228, p <0.01) and to the 
1.15
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Fig.2 HAQ score evolution based on clinical monitorization 
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Fig. 3 General practitioner’ monitorization during the interval 
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rheumatologist (ρs = 0.345, p <0.001). Linear uni - and 
multivariate regression is attributed predictability only to 
the rheumatologist visits for the biological monitoring (β = 
0.209, t = 2.8, p <0.01). 
The standardization of the osteoarticular lesions 
visible by standard radiography of hands and feet allow 
quantification of RA status and assess disease 
progression (using international standardized X-rays 
scores: Sharp - Van der Hejide score). In the study 
population at the end of observation (T1 - T3), over half 
the cases did not benefit from this imaging tool in the 
assessment of the disease lesions (T1: 39.9%; T2: 
63.3%; T3: 62.2 %; p <0.001), while the remaining 
percentage of patients carried out between 1 and 3 
radiographs (hands, feet and frequently lumbar spine) 
(Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are direct correlations between 
radiological and biological examinations at T2 and T3 (ρs 
= 0.280, respectively ρs = 0.228, p <0.01). There is a 
constant association of the radiological exploration with 
hospitalization (ρs = 0.394, p <0.001), with visits to the 
rheumatologist, but not with visits to the primary re 
network (ρs = 0.258, p <0.001). 
Generally, hospitalization is predictive for the 
biological evaluation (β = 0.4, t = 4.5, p <0.001) as for the 
radiological one (β = 0.35, t = 3.8, p <0.001). Cases 
monitoring mainly based on patients’ admission in the 
hospital is reproduced in Figures 6 and 7.  
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Biological exploration  (over 3 sets) and 
radiological evaluation (1-3 X-rays and more than 3 X-
rays) dominate in hospitalized patients compared with 
those who are not hospitalized.  
Looking towards the ambulatory system 
(outpatient care), there is a homogeneous relationship in 
both groups between visits to the rheumatologist and 
performing laboratory investigations (ρs = 0.28, p <0.05) 
and X-ray evaluation (ρs = 0.26, p <0.05). Only in group 
A, visits to the primary care network is correlated with 
laboratory tests (ρs = 0.21, p <0.05). The lack of similar 
relationships in group B, suggests a closer monitoring of 
patients treated with biological agents directly by the 
rheumatologist (patient preference? / decision of the 
physician?), mostly through hospitalization services, 
compared with patients treated with non-biological 
DMARDs .  
In both groups, the disability level has no 
association or predictability role for the rhythm of primary 
care or rheumatologist monitoring. We say that variables 
have an independent relation between each other.  
Trying to determine which are the causes that 
induce the monitoring rhythm in controls to GP or 
rheumatologist, we analyzed the predictability of patients’ 
self-evaluations VAS (pain, activity fatigue) and the 
addressability to primary medical care and 
rheumatologist. Uni-and multivariate linear regression 
show no predictive indicators for calling the healthcare 
services.  
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Fig. 5 X-rays monitoring dynamics 
Fig. 6 Biological monitoring based on hospitalization 
 
Fig. 7 X-rays monitoring based on hospitalization 
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Having noted these data, we can say that an 
unequivocal role in setting the RA monitoring rate rely on 
the human factor. In addition, there is evidence that the 
medical examination laboratory tests and possibly X-rays 
are recommended together: the rheumatologists’ visits 
are associated with performing laboratory tests and X-ray 
evaluation, in both groups (ρs = 0.33, p <0.01), 
respectively (ρs = 0.35; p <0.01). These relations also 
have a predictability potential (for biological exploration: t 
= 5, β = 0.34, p <0.001; for X-ray evaluation: t = 3.6, β = 
0.26, p <0.001).  
The tendency to explore the patient by imaging 
obviously appears during the hospital admission or the 
rheumatologist visits. From this perspective, the 
involvement of the primary care network in monitoring is 
lower. However, there is an increase in the frequency of 
medical checks at GP, which may be connected only with 
non biological DMARDs drug prescription. There is not 
any significant difference in rate of X-ray evaluation 
according to RA age or HAQ category.   
Conclusions 
Clinical monitoring of RA patients to 
rheumatologists has no correlations with disease-
related parameters.  
The visit rate has increased in volume, although 
the evaluated disease parameters have not worsened 
(HAQ score, quantitative self reported on VAS, utility, EQ-
5D VAS). In the same direction, we mention no 
association between visits to rheumatologist and: HAQ 
category, hospitalization, self-reported pain, fatigue and 
disease activity (on VAS), increased consumption of 
NSAIDs or corticosteroids medication. In the absence of 
differentiating clinical monitoring according to the RA 
stage or phase, the most plausible hypothesis involves 
the human factor in determining the tempo of medical 
checks. The lack of improvement in HAQ scores for 
patients who received more intensive clinical surveillance 
(in terms of its rhythm), confirms the decision of the 
physician on clinical monitoring of RA patients.  
 
Clinical monitoring of RA patients by GPs 
has a monthly trend, without distinction based on 
disease features. 
Except for the direct correlation observed only at 
T3, between primary care network monitoring and self 
reported pain, disease activity and fatigue (on VAS), any 
other disease parameters were not associated with GP 
visits. As a result, patients do not seem to appeal for 
medical advice following an unfavorable disease 
evolution, or the proportion of those who fall into this 
category is extremely small. Interestingly, it is noted that 
there is a constant significant association between visits 
to the primary care network and rheumatologist (ρs = 
0.345, p = 0.000). It appears that the hypothesis that RA 
patients who require monthly GP evaluation are similar to 
the ones receiving monthly rheumatologist evaluation. 
Because predictive factors belonging to RA or related 
disorders have not been observed, it appears that for the 
entire cohort, the decision regarding the rate of medical 
monitoring belongs in a large proportion to the clinician 
(GP or rheumatologist).  
 
Biological monitoring of RA cases is not 
differentiated by disease factors 
There is a constant direct correlation between 
the rate of biological monitoring and medical visits in both 
the primary care network (ρs = 0.228, p <0.01) and 
Rheumatology (ρs = 0.345, p <0.001). The evaluation of 
both values in relation to their predictive ability for 
biological monitoring rate, shows that only visits to 
rheumatologists are predictable for biological evaluation 
(β = 0.209, t = 2.8; p <0.01). In other words, patients who 
are presented in a certain pattern in medical practices are 
oriented to the biological exploration according to this 
rate. This kind of relationship is predictable, but has a 
strong particularity because of the lacking associations 
between rate of biological exploration and disease factors. 
Again, the clinician's decision appears in the foreground.  
 
Radiological monitoring of cases is 
insufficient. 
At the end of the observation period, more than 
half the cases did not benefit from an X-ray examination 
to directly assess disease impact (62.2%). We consider 
that an unfavorable aspect in the disease monitoring.  
There is a significantly divergent behavior 
according to the therapeutic groups: the patients receiving 
biological agents are more closely biologically monitored 
(annual average of biological controls 7.50 vs. 6.69 in 
group A, p = 0.08); on the other hand, the patients treated 
with non biological DMARDs are more intensively 
radiological monitored (3.29 annual X-rays compared with 
2.26 in group B, p = 0.01).  
We remind that the RA population is over 9 
years of disease duration and more than 2 years of stable 
background therapy, exceeding early stage of disease, 
which would require a more intensive surveillance.  
All this generally shows an emphasis on clinical 
and biological monitoring parameters, amid a lack of 
aggregation in monitoring algorithm of RA patients in our 
country.  
Biological evaluation allows the assessment of 
tolerability (blood, liver and kidney) and provides relations 
of efficiency (dynamic of the inflammatory syndrome). 
These data, however, occupy a second position in the 
quantification of the therapeutic effectiveness, the clinical 
evaluation (absolutely necessary) being in the foreground. 
An extensive biological monitorization (at the expense of 
clinical and radiological) would not conduct to a 
therapeutic benefit. 
In order to increase the effective monitoring of 
RA patients and to diminish the influence of human factor,  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010  
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we suggest the following guidelines as recommendations: 
a) Rate of the RA biological assessment: 
given the risk of drug toxicity at the start of RA therapy, 
during the first three months of treatment, we suggest a 
monthly biological monitoring.  Subsequently, after this 
period, the biological monitoring should be done at 
intervals of 3 months and whenever required by the 
clinical evolution. In this framework, the minimum 
biological package relating to efficiency and tolerability 
include: CRP or ESR, complete blood count, ALT, 
creatinine, urinalysis;  
b)  Rate of the RA radiological assessment: for 
non-erosive disease, plain X-rays of hands and feet at 6 
months intervals; during erosive RA, plain X-rays of 
hands and feet at intervals of 1 year. It is recommended 
that X-ray lesions are quantified by using a standardized 
international radiological RA score (Sharp, Van der 
Heijde).  
c) Rate of RA clinical evaluation:  
-  It is recommended that the rate of clinical 
monitoring in the primary care network (GPs) is 
overlapped to the biological rate: the first 3 months of 
starting RA therapy - monthly and quarterly thereafter. If 
any adverse events related to tolerability occur, the 
patient will be referred to the rheumatologist;  
-  In the network of specialized rheumatology: 
during any active RA the clinical evaluation should be 
done at 3 months intervals plus any other time, as 
clinically required; during inactive disease, biannual 
clinical assessments. It is recommended that the clinical 
evaluation includes both quantitative self reported of pain 
and disease activity, through VAS (0 to 100 mm, marked 
the extreme) (Figure 8).  
 
How severe is your joint pain, currently?  
Please mark on the scale below a vertical line anywhere between the two ends corresponding to your joint pain today 
 
 
 
 
How active do you think your disease is, currently?  
Please mark on the scale below a vertical line anywhere between the two ends corresponding to your disease activity today 
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